Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bet v 1-specific T-cell receptors are membrane-bound heterodimeric proteins expressed on T lymphocytes that specifically recognize Bet v 1 peptides presented by major histocompatibility complex (MHC) molecules. Bet v 1 is the major allergen in birch pollen and is responsible for triggering allergic responses in sensitized individuals. Upon binding to Bet v 1-MHC complexes, these TCRs initiate T-cell activation, proliferation, and polarization—primarily driving a Th2-type immune response with production of IL-4, IL-5, IL-13, and IgE antibodies. This mechanism underlies the clinical manifestation of birch pollen allergy. Understanding Bet v 1-specific TCRs is critical for developing diagnostic tools and novel allergen immunotherapies, as modulating these T-cell responses can induce immune tolerance and prevent allergic reactions.
Induction of immune tolerance to Bet v 1 by repeated exposure to allergen or hypoallergenic Bet v 1 variants, reducing T-cell activation and skewing of immune response
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bet v 1-specific T-cell receptor (TCR).